Cubist Systematic Strategies, LLC Gilead Sciences, Inc. Put Options Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $126,521 - $159,581	1,900 Added 211.11%	2,800 $234,000
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $915,675 - $1.06 Million	-14,500 Reduced 94.16%	900 $61,000
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $479,586 - $584,843	-6,700 Reduced 30.32%	15,400 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $1.41 Million - $1.6 Million	19,200 Added 662.07%	22,100 $1.79 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $1.26 Million - $1.37 Million	-17,000 Reduced 85.43%	2,900 $217,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $7.69 Million - $8.77 Million	-101,200 Reduced 83.57%	19,900 $1.53 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $974,106 - $1.11 Million	-12,600 Reduced 9.42%	121,100 $10 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $6.05 Million - $8.68 Million	97,000 Added 264.31%	133,700 $11.5 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $595,400 - $680,100	10,000 Added 37.45%	36,700 $2.26 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $1.54 Million - $1.74 Million	26,700 New	26,700 $1.65 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.